Protocol
Individualized nutritional support for hospital inpatients at nutritional risk
In EFFORT, 2,088 medical inpatients at nutritional risk were given individualized nutritional support to reach calorie and protein goals, or standard hospital food.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
Many older people in hospital do not eat enough. In a large trial, patients at risk got a plan from a dietitian to meet their food and protein needs. A month later, fewer had serious problems and fewer had died than patients on normal hospital food. Only one trial has shown this so far.
- What was measured
- Serious problems and deaths within 30 days.
- How big
- Death by day 30 was 7% with nutritional support against 10% with standard food.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 31030981.
- Who it applies to
- Adult medical inpatients at nutritional risk.
- Safety
- No difference in side effects of nutritional support.
- Compared with
- Standard hospital food.
- Certainty
- Grade C, resting on: One large pragmatic randomized trial with hard outcomes.
- What would change this grade
- Could rise to B with: Randomized trial of individualized nutritional support. Who: Older medical inpatients at nutritional risk outside Switzerland. Measured: Death and adverse outcomes at 30 days. Length: At least 6 months.
- Cost
- No price recorded yet.
- Sources
- 1 study cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In EFFORT, 2,088 medical inpatients at nutritional risk were given individualized nutritional support to reach calorie and protein goals, or standard hospital food. By 30 days, 23% had an adverse outcome against 27%, and 7% had died against 10%.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on 30-day adverse outcomes and death. One large randomized trial found fewer adverse outcomes and fewer deaths with individualized nutritional support (Schuetz et al., 2019; PMID 31030981).
WHY NOT Bunder Rule 06 a single positive trial without independent replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. is a C, and this result rests on one trial in Swiss hospitals.
WHAT THIS GRADE DOES NOT COVERpeople who are well nourished, intensive care patients, surgical patients, and oral supplements taken at home after discharge, none of which this trial studied.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Adverse clinical outcome and death at 30 days (hard)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
An independent replication would carry it to B.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Nutritional Support among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Nutritional Support on ClinicalTrials.gov
Dose, form and timing
Not applicable outside hospital.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 463 · November 2026 · First graded.
New record in the gap-report batch. In EFFORT, 2,088 medical inpatients at nutritional risk were given individualized nutritional support to reach calorie and protein goals, or standard hospital food. By 30 days, 23% had an adverse outcome against 27%, and 7% had died against 10%.PMID 31030981
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullOne paper, linked to its PubMed record.
Schuetz et al. (Lancet, 2019; PMID 31030981): EFFORT, pragmatic randomized trial in eight Swiss hospitals, 2,088 medical inpatients at nutritional risk; adverse clinical outcome by day 30 in 23% against 27% (adjusted OR 0.79, 95% CI 0.64 to 0.97); death by day 30 in 7% against 10% (adjusted OR 0.65, 95% CI 0.47 to 0.91); no difference in side effects of nutritional support.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(nutritional support[tiab] OR "oral nutritional supplement*"[tiab]) AND inpatient*[tiab] AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Schuetz et al., 2019, Lancet (PMID 31030981): PubMed lists funding from The Swiss National Science Foundation and the Research Council of the Kantonsspital Aarau, Switzerland.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →